Elsevier

Lung Cancer

Volume 108, June 2017, Pages 29-37
Lung Cancer

Review
Treatment options for EGFR mutant NSCLC with CNS involvement—Can patients BLOOM with the use of next generation EGFR TKIs?

https://doi.org/10.1016/j.lungcan.2017.02.012Get rights and content

Highlights

Abstract

With the use of EGFR TKIs, patient survival is now prolonged and as a consequence, a higher chance of development of CNS metastases has been observed during the course of the disease. CNS metastases remains a therapeutically challenging subset of patient to treat owing to the blood-brain barrier (BBB). Prior to routine EGFR mutation testing, surgical resection, stereotactic radiosurgery and/or whole brain radiation therapy (WBRT) were the main treatment options whereas treatment options for patients with leptomeningeal metastases (LM) included intra-thecal chemotherapy, WBRT, and ventriculo-peritoneal shunting. Unfortunately outcome for both BM and LM remains poor with median survival between 3 and 6 months. Systemic treatment with EGFR TKIs had been effective in the treatment of intracranial metastases but efficacy of early generation TKIs were hampered by its limited BBB penetration. The next generation EGFR TKIs osimertinib and AZD3759 have improved BBB penetration and the BLOOM study of osimertinib and AZD3759 has reported highly promising intracranial efficacy and may herald a new frontier to treat this therapeutically challenging subset of advanced EGFR mutant patients.

Introduction

Lung cancer remains a leading cause of death worldwide and the majority of the non-small-cell lung cancer (NSCLC) is diagnosed in the advanced stage [1]. Brain metastases (BM) and leptomeningeal metastases (LM), are frequent sites of progression, accounting for 10–15% at the time of diagnosis and 30–50% cumulatively throughout the course of the disease [2], [3], [4]. Central nervous system (CNS) metastases can cause significant morbidity including neurological deficits, reduced quality of life and poorer survival with a median survival of 4–6 months [5], [6].

The treatment landscape of NSCLC had undergone a paradigm shift with the discovery of activating epidermal growth factor receptor (EGFR) [7] and subsequent trials have shown EGFR tyrosine kinase inhibitors (TKIs) to be superior to chemotherapy in terms of objective response rate (ORR), progression free survival (PFS) and quality of life [8], [9], [10]. With the use of EGFR TKIs, patient survival is now prolonged and as a consequence, a higher chance of development of brain metastases has been observed during the course of the disease. In a study of NSCLC patients without baseline brain metastases, CNS progression occurred at a rate of about 50% at 3 years [11]. The effect of EGFR-TKI and NSCLC EGFR mutation status on the risk of CNS progression has been published with conflicting results. In a study of patients with advanced NSCLC and somatic EGFR mutations initially treated with gefitinib or erlotinib, the 1- and 2-year cumulative risk of CNS progression was 7% and 19%, respectively [4]. In a larger study, the one and two year cumulative risk of CNS progression was 6%, and 21% in the EGFR-TKI group versus 19%, and 32% in the chemotherapy group [12]. One limitation of these two studies is the risk of CNS progression was not independently examined in a NSCLC cohort without EGFR mutations, thereby limiting the ability to evaluate a possible altered biologic predisposition of EGFR mutated lung cancer for CNS sites.

Whilst the systemic efficacy of EGFR TKIs has been well established, its activity in intracranial disease has, until recently, been less well established [13]. Patients with active or untreated CNS metastases are often excluded from the NSCLC clinical trials leading to the limited data in this patient subpopulation. Some early phase and retrospective data have reported activity of EGFR TKIs in CNS metastases, either as monotherapy or as part of multi-modality approach. Thus this is an area of unmet clinical need and new therapeutic approaches are warranted [4], [14], [15], [16].

This review article aims to review the current strategies in the management of patients with EGFR mutant NSCLC with CNS metastases or LMD with a focus on EGFR TKIs, and in particular, a new generation of EGFR TKI with potentially higher CNS activity.

Section snippets

Brain metastases and blood brain barrier (BBB)

The CNS is shielded by BBB and is considered a pharmacologic sanctuary site. The successful treatment of CNS metastases would need to take into account individual drug pharmacokinetics as the majority of drugs are substrates for the drug efflux transporters P-glycoprotein (P-gp) and breast cancer-resistance protein (BCRP). These transporters are highly expressed in the BBB and actively remove drugs including chemotherapy from CNS [17], [18]. In addition, some chemotherapeutic agents and

Treatment strategies for EGFR mutant NSCLC with brain metastases

Several strategies are available to treat NSCLC patients with EGFR mutant with CNS metastases including the use of local therapy such as surgical resection, stereotactic radiosurgery (SRS) or whole brain radiotherapy (WBRT) and the use of systemic therapy such as chemotherapy and EGFR TKIs (Table 2). More recently, there has been interest in using immune checkpoint inhibitors in patients with advanced NSCLC with brain metastases.

Treatment outcomes for leptomeningeal metastases (LM)

LM is become an increasingly common diagnosis due to prolonged survival of patients with metastatic disease and improved diagnostic methods. LM is detected in 1–28% of NSCLC patients at the time of diagnosis. The time from initial diagnosis to the onset of LM ranges from 7 to 17 months [51], [52], [53], [54], [55]. Patient with leptomeningeal metastases (LM) generally has poor outcome with median survival of around 3–6 months [55], [56]. Traditionally, in the era prior to the introduction of

New strategy: role of next generation EGFR TKIs osimertinib and AZD3759

Unfortunately, treatment options discussed above have its limitations especially for LM and there is need to develop treatment that can cross the BBB effectively. The BLOOM trial (NCT02228369) is a phase I trial investigating patients with advanced EGFR mutant NSCLC patients with CNS metastases and LM comprising of two treatment arms: osimertinib and AZD 3759.

Conclusion

The treatment paradigm of advanced NSCLC has changed dramatically with the discovery of sensitizing EGFR mutations and the effectiveness of EGFR TKI in this molecular subgroup of NSCLC. The development of CNS metastases is common in this patient group and is associated with a reduced quality of life and poorer survival and can often be a therapeutic challenge. Traditional therapies such as surgery or WBRT are associated with modest activity. The current generation of EGFR TKIs are active but

Conflicts of interest

Chee-Seng Tan has received honoraria from AstraZeneca, Merck, Boehringer Ingelheim, Novartis, Eli-Lilly, Eisai and Bristol-Myers Squibb; Byoung Chul Cho has received research funding from Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST and consulting role from Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, Yuhan, Pfizer, Eli Lilly; Ross Soo has received honoraria from Astra-Zeneca, BMS, Boehringer Ingelheim, Lilly, Merck, Novartis, Pfizer, Roche, Taiho and research grant from

Acknowledgements

RAS is supported by the National Medical Research CouncilNMRC/CG/012/2013, the National Research Foundation Singapore, the Singapore Ministry of Education under its Research Centres of Excellence initiative.

REFERENCES (78)

  • R. Sundar et al.

    Immunotherapy in the treatment of non-small cell lung cancer

    Lung Cancer

    (2014)
  • K. Shien et al.

    Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer

    Lung Cancer

    (2016)
  • A.S. Mansfield et al.

    Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer

    Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.

    (2016)
  • S.B. Goldberg et al.

    Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

    Lancet Oncol.

    (2016)
  • C.K. Lee et al.

    Checkpoint inhibitors in metastatic EGFR-Mutated non-Small cell lung cancer-A meta-Analysis

    J. Thorac. Oncol.

    (2017)
  • H.G. Yi et al.

    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI

    Lung Cancer

    (2009)
  • S.J. Lee et al.

    Leptomeningeal carcinomatosis in non–Small-Cell lung cancer patients: impact on survival and correlated prognostic factors

    J. Thorac. Oncol.

    (2013)
  • J.H. Park et al.

    Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era

    Lung Cancer

    (2012)
  • S. Umemura et al.

    Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: okayama Lung Cancer Study Group

    Lung Cancer

    (2012)
  • J.W. Riess et al.

    Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era

    Clin. Lung Cancer

    (2014)
  • S.J. Lee et al.

    Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors

    J. Thorac. Oncol.

    (2013)
  • J. Remon et al.

    Leptomeningeal carcinomatosis in non-small cell lung cancer patients: a continuing challenge in the personalized treatment era

    Cancer Treat. Rev.

    (2017)
  • P.G. Morris et al.

    Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy

    J. Thorac. Oncol.

    (2012)
  • H.-S. Gwak et al.

    Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer

    J. Thorac. Oncol.

    (2013)
  • B.-C. Liao et al.

    Epidermal growth factor receptor tyrosine kinase inhibitors for non-Small-Cell lung cancer patients with leptomeningeal carcinomatosis

    J. Thorac. Oncol.

    (2015)
  • C.-S. Tan et al.

    Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer

    Lung Cancer

    (2016)
  • N.U. Lin et al.

    Response assessment criteria for brain metastases: proposal from the RANO group

    Lancet Oncol.

    (2015)
  • J. Zhao et al.

    Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma

    Clin. Lung Cancer

    (2013)
  • P. Hoffknecht et al.

    Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease

    J. Thorac. Oncol.

    (2015)
  • Y.-L. Wu et al.

    Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)

    Ann. Oncol.

    (2013)
  • J.-E. Kim et al.

    Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis

    Lung Cancer

    (2009)
  • S.J. Park et al.

    Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation

    Lung Cancer

    (2012)
  • T. Iuchi et al.

    Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma

    Lung Cancer

    (2013)
  • A. Jemal et al.

    Global cancer statistics

    CA Cancer J. Clin.

    (2011)
  • A. Mujoomdar et al.

    Clinical predictors of metastatic disease to the brain from non–small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases

    Radiology

    (2007)
  • A. Ali et al.

    Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases

    Curr. Oncol.

    (2013)
  • S. Heon et al.

    Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib

    Clin. Cancer Res.

    (2010)
  • C. D’Antonio et al.

    Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies

    Ther. Adv. Med. Oncol.

    (2014)
  • T.J. Lynch et al.

    Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

    N. Engl. J. Med.

    (2004)
  • Cited by (0)

    View full text